Sun Pharma gets USFDA nod for prostate cancer drug

Sun Pharma had acquired YONSA from Churchill Pharmaceuticals and will commercialise the drug in the US.

Published: 23rd May 2018 10:10 AM  |   Last Updated: 23rd May 2018 10:10 AM   |  A+A-

Sun Pharma | REUTERS

By PTI

NEW DELHI: Drug major Sun Pharmaceutical Industries' subsidiary has received approval from the US health regulator for YONSA, used for treatment of a form of prostate cancer.

Sun Pharma had acquired YONSA from Churchill Pharmaceuticals and will commercialise the drug in the US.

In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said "one of Sun Pharma's wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA) for YONSA.

" YONSA (abiraterone acetate) is a novel formulation in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the company said.

Sun Pharma said Churchill is eligible to receive upfront and sales-linked milestone payments as well as royalties on sales pursuant to an agreement between the two companies to commercialise YONSA in the US.

YONSA in combination with methylprednisolone was filed as a new drug application (NDA) and will be promoted as a branded product in the US, Sun Pharma added.

Shares of Sun Pharma were trading 1.49 per cent higher at Rs 459.75 apiece on BSE.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.